Skip to content
NewsBlazeAU – Lifestyle
Author:
Zymeworks Inc.
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
Zymeworks to Acquire Theravance Biopharma, Inc.
June 29, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
June 15, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
May 13, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
March 30, 2026
←
Previous Page
1
2